Background 30% of people with anogenital warts (AGW) have spontaneous regression of
lesions but there is no way to determine whether a specific lesion will remain. There are a …

Introduction Cutaneous warts are highly prevalent lesions caused by the infection of
keratinocytes by different types of human papillomaviruses. Although cutaneous warts are …

Our objective was to determine the efficacy and safety of imiquimod 5% cream in the
treatment of external genital/perianal warts in an open-label Phase IIIB trial. Patients applied …

Objective. To evaluate if new imiquimod formulations using a shorter treatment duration are
safe and efficacious to treat anogenital warts. Methods. In two studies 534 women≥ 12 …

Background: Postmarketing research has explored the optimal application schedule of
imiquimod 5% cream for treatment of external anogenital warts. Objectives: We systemically …

Introduction Several therapeutic options are available to manage anogenital warts (AGWs).
However, no hierarchy of treatments is provided in the latest European and American …

Objective To review published randomised controlled trials to assess the benefit and harm of
imiquimod in the treatment of external genital warts. Data sources MEDLINE (1966 …

With the licensing of the new drug Imiquimod cream 5%(AldaraTM 3M Health Care) for the
treatment of anogenital warts and its inclusion into clinic guidelines, a case note review audit …

Objective: To investigate the efficacy and safety of imiquimod 5% cream in the treatment of
anogenital warts in a female population. Methods: In two open-label studies, female patients …

Background Anogenital warts (AGWs, condylomata acuminata) are among the most
common STIs and may severely impact quality of life (QoL). Available treatment options are …